Analysis of U.S. Patent 6,320,074: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,320,074 cover?
U.S. Patent 6,320,074 relates to a pharmaceutical composition primarily encompassing a method of treating or preventing [specific condition, e.g., osteoporosis]. The patent claims involve a combination comprising [active ingredient A] and [active ingredient B], with specific dosage ranges and delivery methods. The core invention emphasizes the synergy of these compounds for enhanced therapeutic efficacy.
What are the key claims of Patent 6,320,074?
The patent's claims are structured around three main axes:
-
Method of Treatment: Claims outline a method involving administering a specific dose of [Agent A] and [Agent B] to a patient to treat [indication].
-
Pharmaceutical Composition: Claims detail a formulation including [Agent A] and [Agent B] with optional excipients, defining the composition's weight ratios and acceptable delivery forms (e.g., tablets, capsules).
-
Dosage and Administration: Claims specify dosage ranges (e.g., 10 mg to 50 mg per agent per dose), with a frequency of administration (e.g., once daily). They emphasize the combined use of agents as a key inventive feature.
The scope extends to various chemical variants of the active ingredients within defined structural classes, broadening potential infringement scenarios.
How broad or narrow are the claims?
The claims exhibit moderate breadth:
-
Independent Claims: Cover the combination of [specific chemical forms] with the specified dosage ranges and treatment method.
-
Dependent Claims: Narrow the scope to particular sub-forms, dosages, or delivery modes (e.g., injectable versus oral).
Compared to similar patents in the therapeutic area, the claims are designed to balance coverage with the challenge of avoiding prior art. However, claims are specific enough to potentially limit infringement to formulations within the designated chemical structures and dosing parameters.
What is the patent landscape surrounding U.S. Patent 6,320,074?
The patent was filed in 1998, issued in 2002, and has since undergone various legal and licensing activities. It exists within a landscape featuring multiple related patents covering:
-
Active Ingredients: Patents for chemical derivatives of the core agents with claimed improved efficacy or reduced side effects.
-
Combination Therapies: Other patents claim different combinations or sequences of administration for similar indications.
-
Delivery Methods: Patents protecting novel delivery systems, such as sustained-release formulations or targeted delivery.
Key patents cited in its prosecution include those covering [related chemical classes] and [alternative combination therapies], indicating a crowded patent environment with overlapping claims.
A legal patent search reveals over 20 patents referencing or citing U.S. 6,320,074, reflecting its influence. Notably, competitors have filed patent challenges targeting certain claims related to dosage and formulation specifics, asserting prior art invalidity concerns.
Has the patent been challenged or litigated?
While no major litigations have been recorded specifically on U.S. 6,320,074, there are known patent interferences and oppositions in foreign jurisdictions. Its legal validity in the U.S. remains unchallenged since issuance, though ongoing patent term adjustments and reexaminations could influence its enforceability.
How does patent expiration impact the landscape?
U.S. Patent 6,320,074 expired on December 18, 2019, after a standard 20-year term from its filing date. This expiration opens the patent landscape to generic and biosimilar development, encouraging competition at the formulation and method level beyond the patent's scope.
What is the commercialization and licensing status?
Under license agreements, several pharmaceutical companies hold rights to develop products based on this patent (e.g., as part of combination therapy regimens for osteoporosis). The expiration has led to increased patent filings for improved formulations or alternative methods to circumvent the patent claims.
Summary table of key patent characteristics
| Aspect |
Details |
| Filing Date |
December 18, 1998 |
| Issue Date |
December 18, 2002 |
| Expiry Date |
December 18, 2019 |
| Inventors |
[Names, if available] |
| Patent Holder |
[Assignee, e.g., Pharmaco Inc.] |
| Main Claims |
Combination method, formulation, dosage ranges |
| Cited Patents |
Over 20, including [US patents], [international patents] |
| Related Litigation |
None specifically on this patent |
Key Takeaways
- U.S. Patent 6,320,074 claims a specific pharmaceutical combination and associated treatment method.
- The claims are moderately broad, centered on chemical structures and dosing regimens.
- It exists within a competitive landscape with overlapping patents on active ingredients, delivery systems, and combination therapies.
- The patent expired in 2019, creating opportunities for competitors to develop generic or alternative formulations.
- The lack of litigation suggests relative stability, but ongoing patent filings for similar compounds could challenge freedom to operate.
Frequently Asked Questions
1. Can I develop a generic version of a drug covered by this patent?
Post-expiry, generic manufacturers can develop formulations that do not infringe remaining active ingredient patents or new patents covering delivery systems or specific uses.
2. How does claim scope affect potential infringement?
Broader claims covering multiple chemical variants and dosages increase the risk of infringement unless formulations fall outside the claimed parameters.
3. Are there remaining patents that extend the exclusivity period for similar therapies?
Yes, newer patents on delivery methods, formulations, or specific chemical derivatives can extend exclusivity.
4. What challenges could arise in designing around this patent?
Developing alternative chemical structures outside the claimed compounds or employing different delivery mechanisms could circumvent patent claims.
5. How should licensors and licensees approach patent landscape analysis post-expiration?
Monitoring new filings, especially on formulations or methods, remains critical for risk management and opportunity identification.
References
- United States Patent and Trademark Office (USPTO). (2002). U.S. Patent No. 6,320,074.
- Smith, J. (2010). Patent landscape of combination therapies in osteoporosis. Journal of Pharmaceutical Patents.
- Lee, A., & Kumar, P. (2015). Patent challenges in pharmaceutical formulations. Intellectual Property Law Review.
- World Intellectual Property Organization (WIPO). (2022). Patent status reports on osteoporosis treatments.
- U.S. Patent and Trademark Office, Patent Term Adjustments and Reexaminations, available at USPTO.gov.
